Roche Holding's first-half net profit slid 7% under pressure from exchange rates but strong sales of its cancer therapies prompted the Swiss drug giant to confirm its outlook for the full year.
via WSJ.com: US Business http://ift.tt/1z6iD64
via WSJ.com: US Business http://ift.tt/1z6iD64
Nessun commento:
Posta un commento